In a significant development for cardiac care in Mumbai, Gleneagles Hospital, Parel, has introduced a specialised renal denervation therapy centre in partnership with Medtronic India, targeting the growing issue of resistant hypertension, a condition where patients' blood pressure remains uncontrolled despite multiple medications.
This specialised facility aims to address the needs of patients struggling with high blood pressure, even after being on a range of medications. By combining advanced interventional technology, expert clinical teams, and a structured care approach, the centre promises a holistic, long-term solution for managing hypertension.
The Centre is designed to offer in-depth evaluation, medication optimisation, and access to cutting-edge renal denervation therapy, a procedure that targets overactive nerves in the kidneys, which contribute to elevated blood pressure.
The facility will also provide ongoing patient counseling, lifestyle adjustments, and comprehensive follow-up, aiming to improve overall blood pressure control and reduce the risk of complications such as heart disease, stroke, and kidney failure.
Hypertension, say experts, has become an increasingly pervasive health challenge, linked to modern lifestyle factors such as stress, poor diet, lack of physical activity, and rising obesity rates.
Despite the availability of medication, many patients still struggle to manage their blood pressure effectively. Delayed diagnosis, poor adherence to treatment plans, and a lack of awareness continue to exacerbate the problem. As a result, according to reports, hypertension remains one of the leading causes of premature death globally and a significant contributor to cardiovascular diseases in India.
For your daily dose of medical news and updates, visit: HEALTH
For those with resistant hypertension, the situation is even more dire. These patients’ blood pressure remains stubbornly high, even with multiple drugs, putting them at heightened risk of severe cardiovascular and renal complications. Experts estimate that a substantial portion of hypertensive patients suffer from this condition, and their treatment options have traditionally been limited.
This is where renal denervation therapy comes into play. The procedure works by using radiofrequency energy to selectively ablate renal sympathetic nerves that play a pivotal role in regulating blood pressure. The procedure has shown promise in clinical trials as an effective intervention for resistant hypertension, providing an additional option for patients whose condition is unresponsive to conventional treatment.
“Hypertension may not always show symptoms, but when left uncontrolled, it can be silently harmful, leading to stroke, heart attack, and kidney failure,” said Dr Rahul Gupta, Director Cardiologist at Gleneagles Hospital. “Renal denervation therapy offers a new frontier in treating resistant hypertension and helps us offer an additional option for those whose blood pressure continues to remain high despite treatment.”
The aim, say doctors, is not just to control blood pressure but to prevent complications like heart failure, stroke, kidney damage, and vision loss.
Medtronic, a medical device manufacturing company, will provide the equipment necessary for renal denervation therapy, helping to strengthen the hospital's capabilities in tackling resistant hypertension.
As more patients are diagnosed with hypertension and other lifestyle-related diseases, this new centre at Gleneagles Hospital offers a beacon of hope for those who have not found success with traditional treatments.